<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004005</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067216</org_study_id>
    <secondary_id>P30CA021765</secondary_id>
    <secondary_id>SJCRH-CACO5</secondary_id>
    <secondary_id>NCI-G99-1554</secondary_id>
    <nct_id>NCT00004005</nct_id>
  </id_info>
  <brief_title>Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin</brief_title>
  <official_title>Irinotecan and 5-Fluorouracil/Leucovorin for Patients With Colorectal Carcinoma and Other Refractory Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work&#xD;
      in different ways to stop tumor cells from dividing so they stop growing or die. Radiation&#xD;
      therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy&#xD;
      drug with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with radiation therapy works in treating patients with stage III or stage IV colorectal&#xD;
      carcinoma (cancer), other refractory carcinoma (cancer), or metastatic adenocarcinoma&#xD;
      (cancer) of unknown primary origin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with stage IV colorectal carcinoma or other&#xD;
           carcinomas treated with irinotecan followed by fluorouracil and leucovorin calcium.&#xD;
&#xD;
        -  Determine the disease-free survival of patients with stage III colorectal carcinoma,&#xD;
           other refractory carcinomas, or metastatic adenocarcinomas of unknown primary site&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients with stage III colorectal carcinoma (post surgical resection) receive&#xD;
      irinotecan IV over 1 hour on days 1-5 and days 8-12. Treatment repeats every 3 weeks for 2&#xD;
      courses. Beginning on week 7, patients receive pelvic irradiation, leucovorin calcium IV over&#xD;
      4 hours, and fluorouracil IV over 5-15 minutes beginning 1 hour into leucovorin calcium&#xD;
      infusion on days 1-5. Treatment repeats every 3 weeks for a total of 2 courses. Patients with&#xD;
      no evidence of disease may repeat the above 12-week block of chemotherapy without pelvic&#xD;
      irradiation up to 4 times over 1 year.&#xD;
&#xD;
      Patients with stage IV colorectal carcinoma, other refractory carcinomas, or metastatic&#xD;
      adenocarcinomas of unknown primary site receive the above 12-week block of chemotherapy&#xD;
      (irinotecan, fluorouracil, and leucovorin calcium) with pelvic irradiation (if indicated).&#xD;
      Pelvic irradiation patients with an unresected primary tumor undergo exploratory surgery 4-5&#xD;
      weeks after completion of radiotherapy, even in the absence of visible tumor regression.&#xD;
      Radical resection is attempted to effect local control and control of long term symptoms&#xD;
      related to the primary tumor. Patients with complete response (CR) or partial response (PR)&#xD;
      after both chemotherapy and surgery repeat the above 12-week block of chemotherapy 3 times&#xD;
      over 1 year in the absence of disease progression or unacceptable toxicity. Patients with CR&#xD;
      or PR after chemotherapy but no response after surgery receive irinotecan IV over 1 hour on&#xD;
      days 1-5 and days 8-12 every 3 weeks for 1 year in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with stable disease (SD) or progressive disease after 2&#xD;
      courses of irinotecan and SD, CR, or PR after surgery receive leucovorin calcium and&#xD;
      fluorouracil as above every 3 weeks for 1 year in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Carcinoma of Unknown Primary</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Histologically proven previously untreated stage III or stage IV colorectal&#xD;
                  carcinoma&#xD;
&#xD;
               -  Other carcinomas refractory to standard treatment&#xD;
&#xD;
               -  Metastatic adenocarcinoma of unknown primary site&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 25&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Albumin greater than 3.0 g/dL&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT or SGPT less than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 80 mL/min&#xD;
&#xD;
          -  Urinalysis normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Blood glucose normal&#xD;
&#xD;
          -  Electrolytes normal&#xD;
&#xD;
          -  Prior curatively treated childhood cancer allowed&#xD;
&#xD;
          -  Weight greater than 10th percentile for height&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Lee Furman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>adenocarcinoma of unknown primary</keyword>
  <keyword>newly diagnosed carcinoma of unknown primary</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

